160 related articles for article (PubMed ID: 38814402)
1. Regulatory Considerations for Producing mRNA Vaccines for Clinical Trials.
Schmid A
Methods Mol Biol; 2024; 2786():321-337. PubMed ID: 38814402
[TBL] [Abstract][Full Text] [Related]
2. Considerations for Producing mRNA Vaccines for Clinical Trials.
Schmid A
Methods Mol Biol; 2017; 1499():237-251. PubMed ID: 27987154
[TBL] [Abstract][Full Text] [Related]
3. EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD).
Todde S; Windhorst AD; Behe M; Bormans G; Decristoforo C; Faivre-Chauvet A; Ferrari V; Gee AD; Gulyas B; Halldin C; Peitl PK; Koziorowski J; Mindt TL; Sollini M; Vercouillie J; Ballinger JR; Elsinga PH
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2175-85. PubMed ID: 25081821
[TBL] [Abstract][Full Text] [Related]
4. PCMO L01-Setting Specifications for Biological Investigational Medicinal Products.
Krause SO
PDA J Pharm Sci Technol; 2015; 69(5):569-89. PubMed ID: 26429107
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
6. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
7. Research progress on the quality control of mRNA vaccines.
Hu C; Bai Y; Liu J; Wang Y; He Q; Zhang X; Cheng F; Xu M; Mao Q; Liang Z
Expert Rev Vaccines; 2024; 23(1):570-583. PubMed ID: 38733272
[TBL] [Abstract][Full Text] [Related]
8. Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries.
Gluud C; Kubiak C; Whitfield K; Byrne J; Huemer KH; Thirstrup S; Libersa C; Barraud B; Grählert X; Dreier G; Geismann S; Kuchinke W; Temesvari Z; Blasko G; Kardos G; O'Brien T; Cooney M; Gaynor S; Schieppati A; de Andres F; Sanz N; Kreis G; Asker-Hagelberg C; Johansson H; Bourne S; Asghar A; Husson JM; Demotes-Mainard J
Trials; 2012 Mar; 13():27. PubMed ID: 22452964
[TBL] [Abstract][Full Text] [Related]
9. The conduct of clinical trials and good clinical practices: the sponsor's perspective. Food and Drug Administration.
Robb EJ; Davis DD; Farrington DO
J Anim Sci; 1995 Feb; 73(2):614-9; discussion 619-21. PubMed ID: 7601798
[TBL] [Abstract][Full Text] [Related]
10. Scarce quality assurance documentation in major clinical trial registries for approved medicines used in post-marketing clinical trials.
Doua YJ; Dominicus H; Mugwagwa J; Gombe SM; Nwokike J
Trials; 2019 Apr; 20(1):212. PubMed ID: 30975193
[TBL] [Abstract][Full Text] [Related]
11. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
12. Vaccine INDs: review of clinical holds.
Miller DL; Ross JJ
Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
[TBL] [Abstract][Full Text] [Related]
13. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
[TBL] [Abstract][Full Text] [Related]
14. Regulatory concerns for the chemistry, manufacturing, and controls of oligonucleotide therapeutics for use in clinical studies.
Kambhampati RV; Chiu YY; Chen CW; Blumenstein JJ
Antisense Res Dev; 1993; 3(4):405-10. PubMed ID: 8155982
[TBL] [Abstract][Full Text] [Related]
15. The HIV/AIDS vaccine researchers' orientation to the process of preparing a US FDA application for an investigational new drug (IND): what it is all about and how you start by preparing for your pre-IND meeting.
Shapiro SZ
Vaccine; 2002 Jan; 20(9-10):1261-80. PubMed ID: 11818145
[No Abstract] [Full Text] [Related]
16. Regulatory considerations in vaccine design.
Davenport LW
Pharm Biotechnol; 1995; 6():81-96. PubMed ID: 7551250
[TBL] [Abstract][Full Text] [Related]
17. Current regulatory issues in cell and tissue therapy.
Burger SR
Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
[TBL] [Abstract][Full Text] [Related]
18. Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Apr; 73(82):22800-16. PubMed ID: 18567164
[TBL] [Abstract][Full Text] [Related]
19. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
20. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
